Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07108465

Comparative Experimental Study Between Bupivacaine and Ropivacaine Regarding Efficacy in Third Molar Removal Surgery Under General Anesthesia

The goal of this clinical trial is to compare the efficacy of bupivacaine and ropivacaine in third molar removal surgery under general anesthesia in healthy volunteers. The main question aims to determine whether there is any difference in vital signs, hemostasis and postoperative pain between ropivacaine and bupivacaine in patients undergoing third molars extraction under general anesthesia.

Researchers will compare bupivacaine and ropivacaine in a split-mouth study to determine if one drug is more effective in third molar extraction surgery under general anesthesia (better hemostasis, less postoperative pain, and fewer changes in vital signs). Participants will undergo a single surgical procedure and complete the Visual Analog Scale to record postoperative pain

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Third Molars Extraction

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Hospital de Clínicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, 90040-060, Brazil

Location status: Recruiting

Location contact

Henrique T Oliveira

CONTACT

[email protected]

55 51999601939

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 18 to 60
  • Patients ASA Physical Status Classification I and II
  • Patients with impacted or semi-impacted lower third molars with similar positioning on both sides according to the Pell and Gregory classification

Exclusion criteria

  • Patients who can have surgery under local anesthesia
  • Patients where more procedures are required in the same surgical session

Treatment and study plan

Bupivacaine 0,5%

Drug

Injection of bupivacaine 0,5% in group A

ropivacaine 0,75%

Drug

Injection of ropivacaine 0,75% in group B

Primary outcomes

  1. Evaluate if there is a significant difference between groups in postoperative analgesic capacity using Visual Analog Scale, intraoperative hemostasis and in vital signs during anesthesia.

    Time frame: From surgery to 7 postoperative days

    The Visual Analog Scale (0-10 VAS) can be interpreted as no pain (0), mild (1-3), moderate (4-6),severe (7-9),or worse pain (10)

Study contacts

Contact information is provided by the study sponsor or research team.

Henrique T Oliveira

CONTACT

[email protected]

55 51999601939

Sponsors and collaborators

Lead sponsor

Henrique Tedesco

Other

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Aug 7, 2025
Registry last updated
May 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.